Biora Therapeutics Inc (BIOR)

$0.65

+0.01

(+1.33%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.63
    $0.67
    $0.65
    downward going graph

    3.08%

    Downside

    Day's Volatility :5.97%

    Upside

    2.99%

    downward going graph
  • $0.48
    $3.04
    $0.65
    downward going graph

    26.92%

    Downside

    52 Weeks Volatility :84.38%

    Upside

    78.62%

    downward going graph

Returns

PeriodBiora Therapeutics IncIndex (Russel 2000)
3 Months
-8.86%
0.0%
6 Months
-44.06%
0.0%
1 Year
-78.65%
0.0%
3 Years
-96.58%
-22.3%

Highlights

Market Capitalization
23.7M
Book Value
- $2.48
Earnings Per Share (EPS)
-4.93
Wall Street Target Price
9.75
Profit Margin
0.0%
Operating Margin TTM
-4964.15%
Return On Assets TTM
-125.06%
Return On Equity TTM
0.0%
Revenue TTM
860.0K
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
15800.0%
Gross Profit TTM
1.2M
EBITDA
-67.5M
Diluted Eps TTM
-4.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.88
EPS Estimate Next Year
-1.16
EPS Estimate Current Quarter
-0.45
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Biora Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1400.0%

Current $0.65
Target $9.75

Technicals Summary

Sell

Neutral

Buy

Biora Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biora Therapeutics Inc
Biora Therapeutics Inc
9.65%
-44.06%
-78.65%
-96.58%
-96.58%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biora Therapeutics Inc
Biora Therapeutics Inc
NA
NA
NA
-0.88
0.0
-1.25
NA
-2.48
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biora Therapeutics Inc
Biora Therapeutics Inc
Buy
$23.7M
-96.58%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Biora Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 542.0K → 318.0K (in $), with an average decrease of 41.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -73.45M → 6.46M (in $), with an average increase of 269.8% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 115.8%

Institutional Holdings

  • Athyrium Capital Management LP

    29.97%

  • Vanguard Group Inc

    1.91%

  • Geode Capital Management, LLC

    0.55%

  • Northern Trust Corp

    0.19%

  • TWO SIGMA SECURITIES, LLC

    0.18%

  • BlackRock Inc

    0.18%

Company Information

progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.

Organization
Biora Therapeutics Inc
Employees
58
CEO
Mr. Aditya P. Mohanty M.B.A.
Industry
Miscellaneous

Discover More

FAQs